Literature DB >> 4033695

Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease.

G H Boers, A G Smals, F J Trijbels, B Fowler, J A Bakkeren, H C Schoonderwaldt, W J Kleijer, P W Kloppenborg.   

Abstract

Premature arteriosclerosis and thromboembolic events are well-known complications of homozygous homocystinuria due to cystathionine synthase deficiency. It is unknown whether heterozygosity for homocystinuria predisposes to premature vascular disease. We explored the frequency of excessive homocysteine accumulation after standardized methionine loading in 75 patients presenting with clinical signs of ischemic disease before the age of 50:25 with occlusive peripheral arterial disease, 25 with occlusive cerebrovascular disease, and 25 with myocardial infarction. In seven patients in each of the first two groups but in none of the patients in the third group, heterozygosity for homocystinuria was established on the basis of pathological homocysteinemia after methionine loading and cystathionine synthase deficiency in skin fibroblast cultures. Because the frequency of heterozygosity for homocystinuria in the normal population is 1 in 70 at the most, we conclude that this condition predisposes to the development of premature occlusive arterial disease, causing intermittent claudication, renovascular hypertension, and ischemic cerebrovascular disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4033695     DOI: 10.1056/NEJM198509193131201

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  72 in total

1.  Hyperhomocyst(e)inemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

2.  Lipid peroxidation in homocysteinaemia.

Authors:  H J Blom; D P Engelen; G H Boers; A M Stadhouders; R C Sengers; R de Abreu; M T TePoele-Pothoff; J M Trijbels
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

3.  The effect of a subnormal vitamin B-6 status on homocysteine metabolism.

Authors:  J B Ubbink; A van der Merwe; R Delport; R H Allen; S P Stabler; R Riezler; W J Vermaak
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

4.  Evaluation of total plasma homocysteine in Indian newborns using heel-prick samples.

Authors:  A Radha Rama Devi; S M Naushad; Krishna C Prasad
Journal:  Indian J Pediatr       Date:  2006-06       Impact factor: 1.967

Review 5.  The genetic basis of peripheral arterial disease: current knowledge, challenges, and future directions.

Authors:  Iftikhar J Kullo; Nicholas J Leeper
Journal:  Circ Res       Date:  2015-04-24       Impact factor: 17.367

Review 6.  Disorders of homocysteine metabolism.

Authors:  B Fowler
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

7.  Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.

Authors:  S R Lentz; J E Sadler
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

8.  Reduction-oxidation (Redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone.

Authors:  S C Tyagi; L M Smiley; V S Mujumdar; B Clonts; J L Parker
Journal:  Mol Cell Biochem       Date:  1998-04       Impact factor: 3.396

9.  Arterial endothelial barrier dysfunction: actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system.

Authors:  R S Berman; W Martin
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

Review 10.  Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk.

Authors:  Elisabetta Trabetti
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.